| First Author | Israeli E | Year | 2009 |
| Journal | J Neurochem | Volume | 108 |
| Issue | 2 | Pages | 465-74 |
| PubMed ID | 19012742 | Mgi Jnum | J:143080 |
| Mgi Id | MGI:3822726 | Doi | 10.1111/j.1471-4159.2008.05776.x |
| Citation | Israeli E, et al. (2009) Beta-synuclein occurs in vivo in lipid-associated oligomers and forms hetero-oligomers with alpha-synuclein. J Neurochem 108(2):465-74 |
| abstractText | Alpha-synuclein (alphaS) and beta-synuclein (betaS) are homologous proteins implicated in Parkinson's disease and related synucleinopathies. While alphaS is neurotoxic and its aggregation and deposition in Lewy bodies is related to neurodegeneration, betaS is considered as a potent inhibitor of alphaS aggregation and toxicity. No mechanism for the neuroprotective role of betaS has been described before. Here, we report that similar to alphaS, betaS normally occurs in lipid-associated, soluble oligomers in wild-type (WT) mouse brains. We partially purified betaS and alphaS proteins from whole mouse brain by size exclusion followed by ion exchange chromatography and found highly similar elution profiles. Using this technique, we were able to partially separate betaS from alphaS and further separate betaS monomer from its own oligomers. Importantly, we show that although alphaS and betaS share high degree of similarities, betaS oligomerization is not affected by increasing cellular levels of polyunsaturated fatty acids (PUFAs), while alphaS oligomerization is dramatically enhanced by PUFA. We show the in vivo occurrence of hetero-oligomers of alphaS and betaS and suggest that betaS expression inhibits PUFA-enhanced alphaS oligomerization by forming hetero-oligomers up to a quatramer that do not further propagate. |
